IPIX (Innovation Pharmaceuticals) Cash Flow for Lease Financing: $0.00 Mil (TTM As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Innovation Pharmaceuticals Cash Flow for Lease Financing?

Innovation Pharmaceuticals IPIX -33.33% Cash Flow for Lease Financing is $0.00 Mil as of Sep. 2023.

Innovation Pharmaceuticals's Cash Flow for Lease Financing for the three months ended in Sep. 2023 was $0.00 Mil. Innovation Pharmaceuticals's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Jun. 2023 ), Innovation Pharmaceuticals's Cash Flow for Lease Financing remained the same in Sep. 2023 ($0.00 Mil).

Innovation Pharmaceuticals Cash Flow for Lease Financing Historical Data

* Premium members only.

The historical data trend for Innovation Pharmaceuticals's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation Pharmaceuticals Cash Flow for Lease Financing Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Innovation Pharmaceuticals Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Lease Financing of $0.00 Mil mean?
Innovation Pharmaceuticals (IPIX) has a Cash Flow for Lease Financing of $0.00 Mil as of Sep. 2023. Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing. View historical data on Innovation Pharmaceuticals and its competitors.
Is Innovation Pharmaceuticals' Cash Flow for Lease Financing too high?
Innovation Pharmaceuticals' current Cash Flow for Lease Financing is $0.00 Mil.
How does Innovation Pharmaceuticals' Cash Flow for Lease Financing compare to AXIM and RNAZ?
Innovation Pharmaceuticals' Cash Flow for Lease Financing of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Lease Financing for a Biotechnology company?
A good Cash Flow for Lease Financing depends on the Biotechnology industry context. However, Cash Flow for Lease Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Lease Financing mean?
A high Cash Flow for Lease Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing. View historical data on Innovation Pharmaceuticals and its competitors. Innovation Pharmaceuticals's current Cash Flow for Lease Financing is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation Pharmaceuticals stock overvalued right now?
Innovation Pharmaceuticals (IPIX) has a current Cash Flow for Lease Financing of $0.00 Mil. The current Cash Flow for Lease Financing is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Lease Financing calculated?
Cash Flow for Lease Financing is calculated from a company's financial statements. For Innovation Pharmaceuticals (IPIX), the current Cash Flow for Lease Financing is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation Pharmaceuticals Business Description

Address 301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.